<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587584</url>
  </required_header>
  <id_info>
    <org_study_id>ANES-2018-26660</org_study_id>
    <nct_id>NCT03587584</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine Interscalene Blocks for Rotator Cuff Repair</brief_title>
  <acronym>RCR</acronym>
  <official_title>Comparing Liposomal Bupivacaine to Bupivacaine Interscalene Blocks for Arthroscopic Rotator Cuff Repair Surgery: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare pain control after arthroscopic rotator cuff repair&#xD;
      surgery using either liposomal bupivacaine or bupivacaine when injected in an interscalene&#xD;
      block. Both medications, liposomal bupivacaine and bupivacaine, are standard of care in these&#xD;
      types of surgeries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive preoperative oral multimodal medications consisting of&#xD;
      acetaminophen 975 mg, gabapentin 300 mg, and Celebrex 400 mg.&#xD;
&#xD;
      After completion of the preoperative process the patient will be placed in the supine&#xD;
      position with the head of the bed elevated 30 degrees with standard ASA monitors applied.&#xD;
      Sedation will be provided with midazolam 0-2 mg and propofol 50 mg. The interscalene groove&#xD;
      will be identified with the ultrasound. Using sterile technique, a 21g Nerve block needle&#xD;
      will then be inserted and advanced under ultrasound guidance until it is in the interscalene&#xD;
      groove. Once in the interscalene, 20 mL of local anesthetic will be injected, with 10 mL&#xD;
      deposited at the top of the brachial plexus and 10 mL at the bottom. In the study group, 5 mL&#xD;
      of each 0.5% bupivacaine and LB will be injected at each location. The control group with&#xD;
      have 20 mL of 0.5% bupivacaine divided between the injection sites. The patient will be&#xD;
      monitored in the preoperative area until he/she is brought into the operating room for their&#xD;
      procedure. A working block prior to surgery will be confirmed via sensory testing of the&#xD;
      shoulder.&#xD;
&#xD;
      All patients will undergo a standard induction with propofol 1.5-3.0 mg/kg, ondansetron 4 mg,&#xD;
      dexamethasone 10 mg and ketamine 0.25 mg/kg. A MAC or general with LMA or ETT will be placed&#xD;
      and an opioid sparing technique will occur. Standardized maintenance will be a propofol&#xD;
      infusion without neuromuscular blockers. 25-50 mcg of IV Fentanyl will be utilized for&#xD;
      increases in heart rate greater than 20% or increases in systolic blood pressure above&#xD;
      baseline.&#xD;
&#xD;
      Once in the operating room the surgeon will use 10 mL of 0.25% bupivacaine for skin,&#xD;
      subcutaneous, and intraarticular injection.&#xD;
&#xD;
      When the operation is complete, the patient will be woken up and brought to the PACU. There&#xD;
      the patient will receive IV fentanyl for a pain score of greater than 7. If more than 100 mcg&#xD;
      of fentanyl is given and pain still remains above a 7 then IV hydromorphone will be used. A&#xD;
      dose of 5-10 mg of oral oxycodone (or 2-4 mg of oral hydromorphone) will be given as soon as&#xD;
      the patient is able to tolerate oral medication per standard protocol: If their pain score is&#xD;
      4-6 (on the Visual Analog Scale) then 5mg oral oxycodone (2 mg hydromorphone) can be&#xD;
      administered, if their pain is between 7 to 10 then 10 mg of oxycodone (or 4 mg of&#xD;
      hydromorphone) can be administered. Once the patient meets discharge criteria, they will be&#xD;
      discharged home where each day they will fill out a pain diary. Additionally, a member of the&#xD;
      research team will call the patient for signs of complications and ask the patient their&#xD;
      current pain score, total opioid pills taken and non-opioid pain medication taken at 24, 48,&#xD;
      and 72 hours postoperatively. Additionally, they will perform a Quality of Recovery Score&#xD;
      survey at 72 hours, and 14 days postoperatively. An Ultrasound of the diaphragm will be&#xD;
      completed by a blinded anesthesiologist in the PACU to assess diaphragm function.&#xD;
&#xD;
      All patients will be discharged with acetaminophen 975 mg q6 hours &amp; ibuprofen 600 mg q6&#xD;
      hours, taken in intervals such that the patient is taking one of these medications every 3&#xD;
      hours. And then hydromorphone 2mg pills #60 dosing 1-2 pills q4 hours prn severe pain or&#xD;
      oxycodone 5 mg pills #60 dosing 1-2 pills q 4 hours prn severe pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Actual">June 8, 2021</completion_date>
  <primary_completion_date type="Actual">May 25, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total post-operative opioids sued</measure>
    <time_frame>time from end of surgery through 72 hours after end of surgery</time_frame>
    <description>Total amount of opioid medications used during the post-operative period through 72 hours. Opioids normalized to total morphine equivalents.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total maximal pain scores</measure>
    <time_frame>time from end of surgery through 72 hours after end of surgery</time_frame>
    <description>Sum total of maximal pain scores using numerical rating scale 0-10. 0 is best 10 is worst</description>
  </secondary_outcome>
  <other_outcome>
    <measure>overall benefit of analgesia score</measure>
    <time_frame>survey taken at 72 hours after end of surgery</time_frame>
    <description>score on overall benefit of analgesia survey. Range 0-28. Higher is worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>quality of recovery 15 score</measure>
    <time_frame>survey taken at 72 hours after end of surgery</time_frame>
    <description>score on quality of recovery 15 survey. Range 0-150. Higher is better</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>liposomal bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients receive an interscalene block with liposomal bupivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients receive an interscalene block with bupivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal bupivacaine</intervention_name>
    <description>Experimental</description>
    <arm_group_label>liposomal bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients aged greater than 18 years of age that are undergoing arthroscopic&#xD;
             rotator cuff surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with allergy to local anesthetics&#xD;
&#xD;
          -  Patients with daily use of opioids for more than 3 weeks prior to surgery&#xD;
&#xD;
          -  Patients who refuse&#xD;
&#xD;
          -  Patients with coagulopathy&#xD;
&#xD;
          -  Patients who are non-english speaking&#xD;
&#xD;
          -  Patients who do not have access to a telephone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tenzin Desa</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

